Hematopoietic Progenitor Cell
Collection: A Comparison of COBE
Spectra and Spectra OPTIA Collection
Efficiencies using ACD-A or ACD-A
with Heparin Anticoagulation
James W. Smith, MD, PhD
Patti Latschar, PA-C
Debra Smith, MD, PhD
Mandi Kaiser, RN, HP(ASCP)
Oklahoma Blood Institute
Purpose
• HPC collections have been performed
using the COBE Spectra for many years,
including the use of a validated ACD-A
with Heparin protocol since 2006.
• As transition to the Spectra OPTIA is
needed for HPC collections, we performed
prospective validations using either ACD-A
with heparin (Hep) or ACD-A without
heparin (No hep)
Methods- I
• Patients and donors in auto or allo transplant protocols
and allo research
• Spectra vers 6.1 and OPTIA vers 11.0
• ACD-A with hep uses 3,000 IU hep in 750 mL ACD-A
added at 1:16 ratio to WB
• ACD-A (no hep) added at 1:12 ratio to WB
• Auto patients: 2 to 3 bl vol in 4 hr proc
• Allo donors: 12 to 24 L or 2 bl vol
Methods- II
• Number of subjects:
– Spectra 25, OPTIA Hep 95, No hep 47
• CD34 pos cells by BD FACSCalibur
• MNC by manual differential
• Platelet (CBC) by Sysmex 1700
• Collection Efficiency (CE) calculated by:
– (Total cells in prod)/ (pre X vol processed)
– or
– (Total cells in prod)/ {(pre+post)/2} X vol proc)
Pt Weight (kg)
NS
115
110
NS
105
NS
100
95
90
85
80
Spectra Hep
Optia Hep
Optia No Hep
PRE CD34 Pos (Cells/uL)
NS
130
120
110
100
90
NS
80
NS
70
60
50
40
Spectra Hep
Optia Hep
Optia No Hep
LITERS WB PROCESSED
*
18
17
NS
*
16
15
14
13
12
11
10
Spectra Hep
Optia Hep
Optia No Hep
CD34 CE %
NS
75
70
*
65
NS
60
55
50
45
40
35
30
Spectra Hep
Optia Hep
Optia No Hep
MNC CE %
NS
100
95
90
*
85
*
80
75
70
65
60
55
Spectra Hep
Optia Hep
Optia No Hep
PLT CE %
*
31
29
*
27
*
25
23
21
19
17
15
Spectra Hep
Optia Hep
Optia No Hep
CD34 e6/KG PRODUCT
9
*
8
7
*
6
5
NS
4
3
2
Spectra Hep
Optia Hep
Optia No Hep
ABSOLUTE CD34 PRODUCT (e6)
*
800
700
*
600
500
NS
400
300
200
Spectra Hep
Optia Hep
Optia No Hep
Product % MNC
*
100
98
*
96
NS
94
92
90
88
86
84
82
80
Spectra Hep
Optia Hep
Optia No Hep
HCT of Product
6
*
5
*
4
NS
3
2
1
0
Spectra Hep
Optia Hep
Optia No Hep
HPC Product Volume (mL)
*
500
*
450
400
NS
350
300
250
200
Spectra Hep
Optia Hep
Optia No Hep
AC to Patient (mL)
1250
NS
1200
1150
1100
NS
NS
1050
1000
950
900
850
800
Spectra Hep
Optia Hep
Optia No Hep
Calcium (mg)
4000
NS
3800
3600
3400
3200
3000
2800
2600
2400
2200
2000
Optia Hep
Optia No Hep
Results
• CE for both CD34 and MNC for Spectra: SD for
Hep, NSD for No hep
• CE for platelets for Spectra SD (higher)
compared to either OPTIA protocol
• Product volume, CD34 content, and Hct for
Spectra SD (higher) than either OPTIA product
• Product MNC % SD (higher) but content lower
for both OPTIA protocols
• ACD-A and Ca- NSD for OPTIA protocols
Conclusions
• Use of heparin on Spectra provides good CD34
and MNC CE with reduced citrate effects
• Use of heparin on OPTIA provides reduced CE
of CD34 and MNC, less platelet loss
• OPTIA without heparin provides CE NSD from
Spectra for CD34 with less platelet loss
• OPTIA with or without heparin: NSD for citrate
used or supplemental Ca required
• Current OPTIA- heparin not useful